Residual pituitary enlargement in primary hypothyroidism despite 1 1/2 years of L-thyroxine therapy

Australas Radiol. 1999 Feb;43(1):121-3. doi: 10.1046/j.1440-1673.1999.00610.x.

Abstract

Pituitary hyperplasia consequent to untreated primary hypothyroidism undergoes impressive regression following thyroxine therapy. We describe a young man with primary hypothyroidism and pituitary hyperplasia, who showed significant but incomplete regression of pituitary enlargement despite 18 months of L-thyroxine therapy (1 year in replacement dose (150 micrograms/day) and an additional 6 months in suppressive dose (300 micrograms/day)).

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Humans
  • Hyperplasia
  • Hypothyroidism / complications*
  • Hypothyroidism / drug therapy*
  • Magnetic Resonance Imaging
  • Male
  • Pituitary Gland / pathology*
  • Thyroxine / therapeutic use*

Substances

  • Thyroxine